Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378174753> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4378174753 endingPage "2864" @default.
- W4378174753 startingPage "2859" @default.
- W4378174753 abstract "Abstract Background and purpose During the COVID‐19 pandemic, ocrelizumab administration was frequently postponed because of a lack of safety information and to favour vaccination. The clinical implications of ocrelizumab administration delay in multiple sclerosis (MS) patients were assessed. Methods Relapsing (RMS) and primary progressive (PPMS) MS patients receiving ocrelizumab for at least 6 months at our centre were retrospectively classified, according to the possible occurrence of a delay (≥4 weeks) in treatment administration. Patients were categorized in the extended‐interval dosing (EID) group in the presence of at least one delayed infusion; otherwise they were considered as part of the standard interval dosing (SID) cohort. MS history, magnetic resonance imaging examinations and B‐cell counts were also retrospectively collected and analysed. Results A total of 213 RMS and 61 PPMS patients were enrolled; 115 RMS and 29 PPMS patients had been treated according to the SID regimen, whilst 98 RMS and 32 PPMS patients were included in the EID cohort. Average follow‐up after delay was 1.28 ± 0.7 years in the EID cohort. In RMS, comparing SID and EID patients, no differences were found considering the occurrence of clinical relapses (9.6% vs. 16.3%, p = 0.338), magnetic resonance imaging activity (9.8% vs. 14.1%, p = 0.374) or disability progression (11.3% vs. 18.4%, p = 0.103). Similar findings were observed in PPMS patients. In the pooled EID group, treatment delay correlated with CD19‐positive relative ( r = 0.530, p < 0.001) and absolute ( r = 0.491, p < 0.001) cell counts, without implications on disease activity. Conclusions Sporadic ocrelizumab administration delay granted sustained treatment efficacy in our cohort. Prospective data should be obtained to confirm these observations and set up systematic extended‐interval regimens." @default.
- W4378174753 created "2023-05-26" @default.
- W4378174753 creator A5003010065 @default.
- W4378174753 creator A5004130118 @default.
- W4378174753 creator A5004607254 @default.
- W4378174753 creator A5006120476 @default.
- W4378174753 creator A5013316172 @default.
- W4378174753 creator A5031081647 @default.
- W4378174753 creator A5032023638 @default.
- W4378174753 creator A5038531441 @default.
- W4378174753 creator A5047210273 @default.
- W4378174753 creator A5074408728 @default.
- W4378174753 creator A5083270631 @default.
- W4378174753 creator A5084674707 @default.
- W4378174753 date "2023-06-05" @default.
- W4378174753 modified "2023-10-17" @default.
- W4378174753 title "Ocrelizumab extended‐interval dosing in multiple sclerosis during <scp>SARS‐CoV</scp>‐2 pandemic: a real‐world experience" @default.
- W4378174753 cites W2777074421 @default.
- W4378174753 cites W2802650011 @default.
- W4378174753 cites W3115435993 @default.
- W4378174753 cites W3121831652 @default.
- W4378174753 cites W3165538681 @default.
- W4378174753 cites W3177818710 @default.
- W4378174753 cites W3178550118 @default.
- W4378174753 cites W3202620572 @default.
- W4378174753 cites W4293463320 @default.
- W4378174753 cites W4309660601 @default.
- W4378174753 doi "https://doi.org/10.1111/ene.15891" @default.
- W4378174753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37227923" @default.
- W4378174753 hasPublicationYear "2023" @default.
- W4378174753 type Work @default.
- W4378174753 citedByCount "0" @default.
- W4378174753 crossrefType "journal-article" @default.
- W4378174753 hasAuthorship W4378174753A5003010065 @default.
- W4378174753 hasAuthorship W4378174753A5004130118 @default.
- W4378174753 hasAuthorship W4378174753A5004607254 @default.
- W4378174753 hasAuthorship W4378174753A5006120476 @default.
- W4378174753 hasAuthorship W4378174753A5013316172 @default.
- W4378174753 hasAuthorship W4378174753A5031081647 @default.
- W4378174753 hasAuthorship W4378174753A5032023638 @default.
- W4378174753 hasAuthorship W4378174753A5038531441 @default.
- W4378174753 hasAuthorship W4378174753A5047210273 @default.
- W4378174753 hasAuthorship W4378174753A5074408728 @default.
- W4378174753 hasAuthorship W4378174753A5083270631 @default.
- W4378174753 hasAuthorship W4378174753A5084674707 @default.
- W4378174753 hasConcept C126322002 @default.
- W4378174753 hasConcept C126838900 @default.
- W4378174753 hasConcept C143409427 @default.
- W4378174753 hasConcept C203014093 @default.
- W4378174753 hasConcept C2777288759 @default.
- W4378174753 hasConcept C2778843634 @default.
- W4378174753 hasConcept C2779338263 @default.
- W4378174753 hasConcept C2780640218 @default.
- W4378174753 hasConcept C2780653079 @default.
- W4378174753 hasConcept C2781413609 @default.
- W4378174753 hasConcept C44249647 @default.
- W4378174753 hasConcept C71924100 @default.
- W4378174753 hasConcept C72563966 @default.
- W4378174753 hasConceptScore W4378174753C126322002 @default.
- W4378174753 hasConceptScore W4378174753C126838900 @default.
- W4378174753 hasConceptScore W4378174753C143409427 @default.
- W4378174753 hasConceptScore W4378174753C203014093 @default.
- W4378174753 hasConceptScore W4378174753C2777288759 @default.
- W4378174753 hasConceptScore W4378174753C2778843634 @default.
- W4378174753 hasConceptScore W4378174753C2779338263 @default.
- W4378174753 hasConceptScore W4378174753C2780640218 @default.
- W4378174753 hasConceptScore W4378174753C2780653079 @default.
- W4378174753 hasConceptScore W4378174753C2781413609 @default.
- W4378174753 hasConceptScore W4378174753C44249647 @default.
- W4378174753 hasConceptScore W4378174753C71924100 @default.
- W4378174753 hasConceptScore W4378174753C72563966 @default.
- W4378174753 hasIssue "9" @default.
- W4378174753 hasLocation W43781747531 @default.
- W4378174753 hasLocation W43781747532 @default.
- W4378174753 hasOpenAccess W4378174753 @default.
- W4378174753 hasPrimaryLocation W43781747531 @default.
- W4378174753 hasRelatedWork W1532617462 @default.
- W4378174753 hasRelatedWork W2584761734 @default.
- W4378174753 hasRelatedWork W2615654765 @default.
- W4378174753 hasRelatedWork W2889485921 @default.
- W4378174753 hasRelatedWork W2906439237 @default.
- W4378174753 hasRelatedWork W3030177861 @default.
- W4378174753 hasRelatedWork W3160974410 @default.
- W4378174753 hasRelatedWork W4212881285 @default.
- W4378174753 hasRelatedWork W4296691977 @default.
- W4378174753 hasRelatedWork W4377136868 @default.
- W4378174753 hasVolume "30" @default.
- W4378174753 isParatext "false" @default.
- W4378174753 isRetracted "false" @default.
- W4378174753 workType "article" @default.